Insmed Inc INSM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
-
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
-
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
-
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
-
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
-
Insmed to Present at May 2026 Investor Conferences
-
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
Trading Information
- Previous Close Price
- $109.14
- Day Range
- $107.33–110.67
- 52-Week Range
- $90.39–212.75
- Bid/Ask
- $109.00 / $110.55
- Shares Outstanding
- 216.75M
- Market Cap
- $23.87B
- Volume/Avg
- 2M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.90
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,664
- Website
- https://www.insmed.com
Valuation
|
Metric
|
INSM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 33.82 |
Price/Sales | 27.90 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INSM
|
|---|---|
Quick Ratio | 3.88 |
Current Ratio | 4.47 |
Interest Coverage | −14.39 |
Quick Ratio
INSM
Profitability
|
Metric
|
INSM
|
|---|---|
Return on Assets (Normalized) | −41.45% |
Return on Equity (Normalized) | −121.78% |
Return on Invested Capital (Normalized) | −59.02% |
Return on Assets
INSM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?F&m@>$ | LOCK|X#L^B | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&XW^nN | LOCK|^J<! | $69B | |||
| argenx SE ADR
ARGX
| LOCK|<@^<@^ | LOCK|rk | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|nQ?LVhk | LOCK|WDrM | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%XFN&^ | LOCK|?D | $36B | |||
| Moderna Inc
MRNA
| LOCK|>xhfpw | LOCK|jb | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gn%^TPzl | LOCK|s@$!r | $25B | |||
| Incyte Corp
INCY
| LOCK|JLGxsD | LOCK|y! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|F^jyf#< | LOCK|RH | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|>>wr>rf | LOCK|C< | $16B |
United States